Who are Kengreal's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Effient, Plavix, prostacyclin, Brilinta, Brilinta, atorvastatin and clopidogrel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cangrelor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Kengreal — Competitive Intelligence Brief

Kengreal (CANGRELOR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 Platelet Inhibitor [EPC]. Area: Metabolic.

marketed P2Y12 Platelet Inhibitor [EPC] P2Y purinoceptor 12 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Kengreal (CANGRELOR) — Chiesi. Kengreal blocks the action of ADP on platelets, preventing platelet activation and aggregation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Kengreal TARGET	CANGRELOR	Chiesi	marketed	P2Y12 Platelet Inhibitor [EPC]	P2Y purinoceptor 12	2015-01-01
Effient	PRASUGREL	Cosette	marketed	P2Y12 Platelet Inhibitor	P2Y purinoceptor 12	2009-01-01
Plavix	clopidogrel	Generic (originally Sanofi/BMS)	marketed	Thienopyridine antiplatelet agent	Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter	1997-11-17
prostacyclin	prostacyclin	United Therapeutics	marketed		P2Y purinoceptor 12, Prostacyclin receptor, Prostaglandin E2 receptor EP1 subtype
Brilinta	ticagrelor	AstraZeneca	marketed	P2Y12 Platelet Inhibitor [EPC]	Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12
Brilinta	Brilinta	AstraZeneca	marketed		Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12
atorvastatin and clopidogrel	atorvastatin and clopidogrel	Ospedale Misericordia e Dolce	marketed	Statin and P2Y12 platelet inhibitor combination	HMG-CoA reductase and P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2030-04-17 — Brilinta · 8425934 · Formulation · US
2030-10-17 — Brilinta · 8425934*PED · Compound · US
2036-01-27 — Brilinta · 10300065 · Method of Use · US
2036-07-27 — Brilinta · 10300065*PED · Compound · US

Sponsor landscape (P2Y12 Platelet Inhibitor [EPC] class)

AstraZeneca · 1 drug in this class
Chiesi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Kengreal — Competitive Intelligence Brief. https://druglandscape.com/ci/cangrelor. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab